StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a report issued on Tuesday.

Several other research firms also recently commented on ANIP. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $79.75.

Remove Ads

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded up $3.00 during mid-day trading on Tuesday, hitting $68.12. The company had a trading volume of 291,286 shares, compared to its average volume of 268,260. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock's 50 day moving average price is $62.34 and its 200-day moving average price is $59.08. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.00. The company has a market capitalization of $1.48 billion, a P/E ratio of -123.85 and a beta of 0.49.

Insider Buying and Selling

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company's stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $191,776 over the last three months. 12.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. FMR LLC boosted its stake in shares of ANI Pharmaceuticals by 27.5% during the third quarter. FMR LLC now owns 18,401 shares of the specialty pharmaceutical company's stock valued at $1,098,000 after purchasing an additional 3,972 shares during the period. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at about $222,000. Janus Henderson Group PLC boosted its position in ANI Pharmaceuticals by 83.7% in the 3rd quarter. Janus Henderson Group PLC now owns 9,510 shares of the specialty pharmaceutical company's stock valued at $568,000 after buying an additional 4,333 shares during the period. Stifel Financial Corp bought a new position in ANI Pharmaceuticals in the 3rd quarter worth about $418,000. Finally, State Street Corp increased its position in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after acquiring an additional 58,698 shares during the period. Institutional investors own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.